Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

[1]  W. Oyen,et al.  Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. , 2018, European urology.

[2]  N. Rioux-Leclercq,et al.  The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma , 2018, PloS one.

[3]  E. Visser,et al.  Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  A. Belldegrun,et al.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.

[5]  S. Vanbelle.  Comparing dependent kappa coefficients obtained on multilevel data , 2017, Biometrical journal. Biometrische Zeitschrift.

[6]  Yiyan Liu.  The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations , 2016, Front. Oncol..

[7]  E. Plimack,et al.  Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. , 2016, The Lancet. Oncology.

[8]  Arun Z. Thomas,et al.  Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. , 2016, European urology.

[9]  P. Russo,et al.  Subcentimeter pulmonary nodules are not associated with disease progression in patients with renal cell carcinoma. , 2015, The Journal of urology.

[10]  H. Hollema,et al.  89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment , 2015, The Journal of Nuclear Medicine.

[11]  T. Choueiri,et al.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.

[12]  W. Oyen,et al.  Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. , 2013, European urology.

[13]  E. Oosterwijk,et al.  Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma , 2013, International journal of molecular sciences.

[14]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[15]  Shinichi Nakagawa,et al.  A general and simple method for obtaining R2 from generalized linear mixed‐effects models , 2013 .

[16]  Steven P. Larson,et al.  Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Belldegrun,et al.  CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. , 2009, The Journal of urology.

[20]  J. Cheville,et al.  Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Grankvist,et al.  Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma , 2007, BJU international.

[22]  W. Oyen,et al.  Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  R. Figlin,et al.  Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. , 2003, Urology.

[24]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[26]  R. Brakenhoff,et al.  Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 , 2000, International journal of cancer.

[27]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[29]  R. Figlin,et al.  The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. , 2002, Clinical nephrology.